- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01733524
Pet Ownership and Glucose Control in Type 1 Diabetes
Impact of Pet Ownership on Glycemic Control in Youth With Type 1 Diabetes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Type 1 diabetes mellitus (T1DM) affects 151,000 children and adolescents in the United States. Youth with T1DM are at a high risk for multiple psychosocial co-morbidities including poor health related quality of life (HRQoL) which is linked to medication non-compliance and increased risk for diabetes-related complications. Any reduction in the psychosocial adjustment difficulties related to T1DM could improve the medical outcome of children with T1DM.
Current standards for diabetes management reflect the need to maintain glucose control within a normal range. However, numerous reports indicate that normalization of blood glucose levels is seldom attainable in children and adolescents. Family cohesion, positive coping strategies, younger age of onset, social support and adequate self-regulatory behavior are found to favorably influence glycemic control. One may conclude that the presence of a companion animal, capable of enhancing the positive factors named above, would augment the array of tools available for the successful management of chronic illnesses such as T1DM.
There is a lack of studies assessing the impact of pet ownership on the health and well-being of adolescents. The process of caring for, loving and being loved by a companion animal could offer direct and/or indirect benefits to the HRQoL in children with T1DM. To the investigators' knowledge, there are no studies examining the impact of pet ownership on glycemic control and HRQoL in youth with T1DM.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- English-speaking patients
- 10 to 18 years
- diagnosed with type 1 diabetes for at least 12 months
- poor diabetes control as defined by having a hemoglobin A1c value > 8%
Exclusion Criteria:
- type 2 diabetes
- developmental delay
- current participation in another study that may impact glycemic control
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Sham Comparator: Picture of a fish
Participants will receive a picture of a betta fish.
|
Participants will receive a picture of a betta fish.
|
Active Comparator: Pet fish
Participants will receive a betta fish and the supplies to care for the fish for a one year time period.
|
Participants will receive a betta fish and the supplies to care for the fish for a one year time period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glycemic control
Time Frame: 12 months
|
Hemoglobin A1c values
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HRQoL
Time Frame: 9 months
|
Generic and diabetes-specific health related quality of life
|
9 months
|
Self Management of Diabetes in Adolescents
Time Frame: 12 months
|
Self management of diabetes in adolescence questionnaire
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Health care burden
Time Frame: 12 months
|
Number of visits to the Emergency Department and inpatient hospitalizations for poor glycemic control
|
12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Olga T Gupta, MD, UT Southwestern
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1R03HD071263-01 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute of Biocybernetics...UnknownType 1 Diabetes Mellitus With Hyperglycemia | Type 1 Diabetes Mellitus With HypoglycaemiaPoland
Clinical Trials on Picture of a fish
-
Seoul National University Bundang HospitalRecruitingPain, Postoperative | Analgesia | Artificial Intelligence | Facial ExpressionKorea, Republic of
-
Retina GlobalVisionQuest Biomedical LLCCompletedDiabetic RetinopathyBolivia
-
University Hospital, LilleRecruiting
-
Finnish Institute for Health and WelfareUniversity of Oslo; Academy of FinlandCompletedHypertension | PrehypertensionFinland
-
University of OstravaTechnical University of Ostrava; DAP ITRecruiting
-
Charite University, Berlin, GermanyCompletedHealthy Older AdultsGermany
-
Charite University, Berlin, GermanyWithdrawn
-
Charite University, Berlin, GermanyCompletedHealthy Older AdultsGermany
-
University of AlbertaStollery Children's Hospital FoundationCompletedInflammation | Cardiac Surgical ProceduresCanada
-
Jeju National University HospitalCompletedObesity | Diabetes MellitusKorea, Republic of